<?xml version="1.0" encoding="UTF-8"?>
<results title="tropicalVirus">
 <result pre="661447746291 doi: 10.1038/s41598-019-46291-9 : Article Human Polyclonal Antibodies Prevent Lethal" exact="Zika" post="Virus Infection in Mice BrancheEmilie1SimonAyo Yila2SheetsNicholas1KimKenneth1BarkerDouglas2NguyenAnh-Viet T.1SahotaHarpreet3YoungMatthew Perry1SalgadoRebecca1MamidiAnila1ViramontesKarla M.1CarnelleyTrevor2QiuHongyu2Elong"/>
 <result pre="To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Abstract" exact="Zika" post="virus (ZIKV) is an emerging mosquito-borne flavivirus that represents"/>
 <result pre="mosquito-borne flavivirus that represents a major threat to global health." exact="ZIKV" post="infections in adults are generally asymptomatic or present with"/>
 <result pre="asymptomatic or present with mild symptoms. However, recent outbreaks of" exact="ZIKV" post="have revealed that it can cause Congenital Zika Syndrome"/>
 <result pre="outbreaks of ZIKV have revealed that it can cause Congenital" exact="Zika" post="Syndrome in neonates and Guillain-Barré syndrome in adults. Currently,"/>
 <result pre="with high neutralizing anti-ZIKV titers as a therapeutic candidate against" exact="ZIKV" post="infection using a model of ZIKV infection in Ifnar1−/−"/>
 <result pre="a therapeutic candidate against ZIKV infection using a model of" exact="ZIKV" post="infection in Ifnar1−/− mice. ZIKV-IG successfully protected mice from"/>
 <result pre="infection in Ifnar1−/− mice. ZIKV-IG successfully protected mice from lethal" exact="ZIKV" post="challenge. In particular, ZIKV-IG treatment at 24 hours after lethal"/>
 <result pre="ZIKV challenge. In particular, ZIKV-IG treatment at 24 hours after lethal" exact="ZIKV" post="infection improved survival by reducing weight loss and tissue"/>
 <result pre="viable candidate for further development as a treatment against human" exact="ZIKV" post="infection. Subject terms Protein vaccines Viral infection Funding Emergent"/>
 <result pre="Viral infection Funding Emergent BioSolutions Canada Inc, Winnipeg, Canada Introduction" exact="Zika" post="virus (ZIKV) is an arthropod-borne virus belonging to the"/>
 <result pre="arthropod-borne virus belonging to the family Flaviviridae, similar to dengue," exact="West Nile," post="Japanese encephalitis, and yellow fever viruses1. ZIKV was first"/>
 <result pre="to dengue, West Nile, Japanese encephalitis, and yellow fever viruses1." exact="ZIKV" post="was first identified in a sentinel rhesus monkey in"/>
 <result pre="was first identified in a sentinel rhesus monkey in the" exact="Zika" post="Forest of Uganda in 1947 and was isolated from"/>
 <result pre="1947 and was isolated from mosquitoes (Aedes africanus) in 19482." exact="ZIKV" post="is transmitted through the bite of infected female Ae."/>
 <result pre="sexual transmission12. From the 1950’s to 1990’s, serological evidence of" exact="ZIKV" post="was reported in multiple Asian13–16 and African17–22 countries, but"/>
 <result pre="countries, but no outbreaks and only 14 cases of human" exact="ZIKV" post="disease were described17,22–25. The first ZIKV outbreak was observed"/>
 <result pre="14 cases of human ZIKV disease were described17,22–25. The first" exact="ZIKV" post="outbreak was observed in 2007 on Yap Island in"/>
 <result pre="after these outbreaks in part due to the emergence of" exact="ZIKV" post="outside its previously known geographic range, showing the potential"/>
 <result pre="is present. In addition, prior to the French Polynesia outbreak," exact="ZIKV" post="was known to be asymptomatic or cause only mild"/>
 <result pre="maculopapular rashes, and conjunctivitis). However, since 2007, severe complications of" exact="ZIKV" post="infection, in particular Guillain–Barré Syndrome in adults31,32 and Congenital"/>
 <result pre="ZIKV infection, in particular Guillain–Barré Syndrome in adults31,32 and Congenital" exact="Zika" post="Syndrome in babies born to ZIKV-infected women7,8,33–36 have been"/>
 <result pre="have been observed. These findings led the WHO to declare" exact="ZIKV" post="a public health emergency of international concern in 2016"/>
 <result pre="studies have demonstrated that mAbs can provide therapeutic protection against" exact="ZIKV" post="in various human and mouse models44, only a single"/>
 <result pre="therapeutic potential of human pAbs produced from transchromosomal cows against" exact="ZIKV" post="infection in mice. As no study has as yet"/>
 <result pre="evaluate the therapeutic potential of ZIKV-IG. Prior to the recent" exact="ZIKV" post="epidemics, only a few studies had been performed in"/>
 <result pre="performed in mice and these required many serial passages of" exact="ZIKV" post="in mice to produce consistent disease phenotypes45–47. Within the"/>
 <result pre="substantial efforts have been focused on generating new mouse models." exact="ZIKV" post="evades the anti-viral type I interferon (IFN) response, in"/>
 <result pre="I IFN receptor (Ifnar) signaling in a species-specific manner by" exact="ZIKV" post="explains the more severe pathogenesis of ZIKV infection in"/>
 <result pre="species-specific manner by ZIKV explains the more severe pathogenesis of" exact="ZIKV" post="infection in mice with immature or compromised immune systems"/>
 <result pre="of the Ifnar1 signaling increases susceptibility of mice to lethal" exact="ZIKV" post="infection. Accordingly, wild type mice treated with blocking anti-Ifnar1"/>
 <result pre="II IFN receptors59–61 have been widely used as models of" exact="ZIKV" post="infection. We measured the effectiveness of ZIKV-IG therapy on"/>
 <result pre="liver, sciatic nerves and brain, of Ifnar1−/− mice following lethal" exact="ZIKV" post="challenge. ZIKV-IG treatment at 24 hrs post-infection increased survival"/>
 <result pre="that a single dose of ZIKV-IG is efficacious against lethal" exact="Zika" post="disease in a highly stringent mouse challenge model. Results"/>
 <result pre="Ifnar1−/− mice To evaluate the therapeutic efficacy of ZIKV-IG against" exact="ZIKV" post="infection, Ifnar1−/− mice were infected with ZIKV (strain FSS13025,"/>
 <result pre="of ZIKV-IG against ZIKV infection, Ifnar1−/− mice were infected with" exact="ZIKV" post="(strain FSS13025, 1.0 × 103 FFU/mouse, retro-orbital (r.o.) route) and then"/>
 <result pre="used for this study exhibits high neutralization activity against multiple" exact="ZIKV" post="strains, including strain FSS13025 (Supplementary Fig. S1). Animals were"/>
 <result pre="A dose-dependent effect on mortality, weight changes and severity of" exact="ZIKV" post="disease was observed in ZIKV-IG treated animals compared to"/>
 <result pre="dose is the most efficacious of the doses tested against" exact="ZIKV" post="infection in this mouse model. Figure 1 ZIKV-IG treatment"/>
 <result pre="of Ifnar1−/− mice (n = 8) were infected with 1.0 × 103 FFU of" exact="ZIKV" post="strain FSS13025 via a retro-orbital (r.o.) route. At 24"/>
 <result pre="reduces viral burden in sera and key target organs of" exact="ZIKV" post="tropism (spleen, kidneys, liver, sciatic nerves, and brain). Ifnar1−/−"/>
 <result pre="liver, sciatic nerves, and brain). Ifnar1−/− mice were infected with" exact="ZIKV" post="(strain FSS13025, 1.0 × 103 FFU/mouse, r.o. route) followed by treatment"/>
 <result pre="levels of viral RNA but lower levels of BHK cell-infectious" exact="ZIKV" post="(−1.3-fold, p = 0.009) than control mice at day 3 p.i."/>
 <result pre="treatment decreases viral burden in key non-neuronal target organs of" exact="ZIKV" post="in mice. Groups of Ifnar1−/− mice (n = 6) were infected"/>
 <result pre="of Ifnar1−/− mice (n = 6) were infected with 1.0 × 103 FFU of" exact="ZIKV" post="strain FSS13025 (via r.o. route). At 24 hrs p.i.,"/>
 <result pre="standard error of the mean. As the major consequences of" exact="ZIKV" post="infection are related to infection of the nervous system,"/>
 <result pre="vs. control mice. At day 3 p.i., similar levels of" exact="ZIKV" post="RNA and infectious particles were present in the sciatic"/>
 <result pre="7 p.i., both viral RNA (−2.6-fold, p = 0.009) and BHK cell-infectious" exact="ZIKV" post="(−3.2-fold, p = 0.009) levels were reduced in the sciatic nerves"/>
 <result pre="and Supplementary Tables S2). Only low levels of BHK cell-infectious" exact="ZIKV" post="were detected at day 3 p.i. in the brains"/>
 <result pre="from 50 mg/kg ZIKV-IG-treated mice contained reduced levels of BHK cell-infectious" exact="ZIKV" post="relative to control mice (−3.5-fold, p = 0.009) (Fig. 3B and"/>
 <result pre="Supplementary Table S2). Viral RNA (−1.3-fold, p = 0.009) and BHK cell-infectious" exact="ZIKV" post="(−1.8-fold, p = 0.009) levels were also decreased the day 7"/>
 <result pre="the sciatic nerves and brain being major target organs of" exact="ZIKV" post="at a later time point post infection in this"/>
 <result pre="of Ifnar1−/− mice (n = 6) were infected with 1.0 × 103 FFU of" exact="ZIKV" post="strain FSS13025 (via r.o. route). At 24 hrs p.i.,"/>
 <result pre="route) with vehicle (circle) or 50 (square) mg/kg ZIKV-IG. (A)" exact="ZIKV" post="RNA levels, as measured by qRT-PCR and (B) infectious"/>
 <result pre="ZIKV RNA levels, as measured by qRT-PCR and (B) infectious" exact="ZIKV" post="levels, as determined by FFA analyses in the sciatic"/>
 <result pre="To confirm the robust efficacy of 50 mg/kg ZIKV-IG treatment against" exact="ZIKV" post="infection in this mouse model, we next localized ZIKV"/>
 <result pre="against ZIKV infection in this mouse model, we next localized" exact="ZIKV" post="in tissues by performing immunohistochemistry (IHC) for expression of"/>
 <result pre="ZIKV in tissues by performing immunohistochemistry (IHC) for expression of" exact="ZIKV" post="nonstructural protein 2B (NS2B), which is absent in virions"/>
 <result pre="(p = 0.006) (Fig. 4D). Thus, 50 mg/kg ZIKV-IG treatment is effective against" exact="ZIKV" post="infection in this highly stringent challenge model, as assessed"/>
 <result pre="50 mg/kg ZIKV-IG, lower doses of ZIKV-IG are less effective against" exact="ZIKV" post="infection, reducing viral burden in select tissues. Figure 4"/>
 <result pre="viral burden in select tissues. Figure 4 ZIKV-IG treatment decreases" exact="ZIKV" post="NS2B expression in the liver and brain of ZIKV-infected"/>
 <result pre="of Ifnar1−/− mice (n = 8) were infected with 1.0 × 103 FFU of" exact="ZIKV" post="strain FSS13025 (via r.o. route). At 24 hrs p.i.,"/>
 <result pre="ZIKV-IG. At day 7 p.i., tissues were harvested to detect" exact="ZIKV" post="NS2B expression via IHC. (A) NS2B expression in the"/>
 <result pre="other signs of injury in ZIKV-IG-treated and control mice following" exact="ZIKV" post="infection, hematoxylin &amp;amp; eosin-stained brain slide sections were examined"/>
 <result pre="the therapeutic potential of human anti-ZIKV pAb (ZIKV-IG) against lethal" exact="ZIKV" post="infection in a highly stringent mouse model. ZIKV-IG treatment"/>
 <result pre="of ZIKV-IG as a candidate for prophylaxis or treatment of" exact="Zika" post="disease. A variety of Abs, including mAbs isolated from"/>
 <result pre="in transchromosomal bovines65 were shown to have therapeutic potential against" exact="ZIKV" post="infection in mice. Similarly, transfer of convalescent sera from"/>
 <result pre="of convalescent sera from a human to pregnant mice prevented" exact="ZIKV" post="infection and associated fetal birth defects66, and convalescent human"/>
 <result pre="ZIKV-infected individuals were able to neutralize both African and Asian" exact="ZIKV" post="strains in vitro67. Here, we report that a single"/>
 <result pre="at 24 hrs post-infection in Ifnar1−/− mouse model of lethal" exact="ZIKV" post="infection prevented both severe disease development and mortality. In"/>
 <result pre="both severe disease development and mortality. In addition, ZIKV-IG reduced" exact="ZIKV" post="burden and ZIKV-induced tissue damage in target organs, confirming"/>
 <result pre="ZIKV-induced tissue damage in target organs, confirming therapeutic potential against" exact="ZIKV" post="infection. Recent outbreaks of several emerging and re-emerging viral"/>
 <result pre="was purified using a validated hyperimmune platform manufacturing process68. Although," exact="ZIKV" post="strains have been phylogenetically characterized into African and Asian/American"/>
 <result pre="premise is supported by the report that primary infection with" exact="ZIKV" post="African strain in macaques protected the animals from secondary"/>
 <result pre="in macaques protected the animals from secondary heterologous re-challenge with" exact="ZIKV" post="Asian strain69. Thus, an effective ZIKV therapeutic candidate could"/>
 <result pre="secondary heterologous re-challenge with ZIKV Asian strain69. Thus, an effective" exact="ZIKV" post="therapeutic candidate could potentially neutralize infection with any of"/>
 <result pre="therapeutic candidate could potentially neutralize infection with any of the" exact="ZIKV" post="virus lineages. Our in vitro potency based on anti-ZIKV"/>
 <result pre="vivo mouse results provide evidence that ZIKV-IG can effectively neutralize" exact="ZIKV" post="infection. Development of Ab products intended for use as"/>
 <result pre="of Ab products intended for use as a therapy against" exact="ZIKV" post="infection should consider the risk of antibody dependent enhancement"/>
 <result pre="the ADE process, pre-existing non- or sub-neutralizing Abs that recognize" exact="DENV" post="enhance subsequent DENV infection and pathogenesis76–78. ZIKV is antigenically"/>
 <result pre="pre-existing non- or sub-neutralizing Abs that recognize DENV enhance subsequent" exact="DENV" post="infection and pathogenesis76–78. ZIKV is antigenically and genetically similar"/>
 <result pre="Abs that recognize DENV enhance subsequent DENV infection and pathogenesis76–78." exact="ZIKV" post="is antigenically and genetically similar to DENV with ~56%"/>
 <result pre="infection and pathogenesis76–78. ZIKV is antigenically and genetically similar to" exact="DENV" post="with ~56% genome sequence homology79, with in vitro and"/>
 <result pre="and in vivo mouse studies demonstrating that Ab response to" exact="DENV" post="and ZIKV can cross-react and cross-enhance infection and pathogenesis"/>
 <result pre="vivo mouse studies demonstrating that Ab response to DENV and" exact="ZIKV" post="can cross-react and cross-enhance infection and pathogenesis of each"/>
 <result pre="macaque and mouse studies have provided further support for pre-existing" exact="ZIKV" post="Ab-mediated enhancement of subsequent DENV infection and disease severity84–86,"/>
 <result pre="provided further support for pre-existing ZIKV Ab-mediated enhancement of subsequent" exact="DENV" post="infection and disease severity84–86, passive transfer of vaccine-induced Abs"/>
 <result pre="infection and disease severity84–86, passive transfer of vaccine-induced Abs before" exact="ZIKV" post="challenge did not result in ZIKV infection enhancement or"/>
 <result pre="of vaccine-induced Abs before ZIKV challenge did not result in" exact="ZIKV" post="infection enhancement or disease in non-pregnant mice and monkeys87,88."/>
 <result pre="sub-protective doses of ZIKV-IG showed no evidence for ADE of" exact="ZIKV" post="infection in our mouse model as suggested by both"/>
 <result pre="mode of infection. Whether ADE is clinically relevant to human" exact="Zika" post="disease is currently unknown, and thus, the possibility of"/>
 <result pre="currently unknown, and thus, the possibility of ZIKV-IG-mediated ADE for" exact="Zika" post="clinical disease remains a theoretical question for the development"/>
 <result pre="performed to assess whether ZIKV-IG has the potential to enhance" exact="DENV" post="infection when given under pre-exposure setting. In summary, we"/>
 <result pre="of ZIKV-IG 24 hrs after infection protected mice against lethal" exact="ZIKV" post="infection. Non-protective doses of ZIKV-IG did not induce ADE"/>
 <result pre="infection. Non-protective doses of ZIKV-IG did not induce ADE of" exact="ZIKV" post="infection. These results provide the evidence that, at appropriate"/>
 <result pre="treatment could be effective at preventing the deleterious effects of" exact="ZIKV" post="in humans. Therefore, further testing in relevant pregnancy models"/>
 <result pre="in this study are outlined in Supplementary Table S3. Virus" exact="ZIKV" post="strains MR766, FSS13025, and PRVABC59 were obtained from the"/>
 <result pre="with 5% CO2 for 1 hr with either 1 × 105 FFU of" exact="ZIKV" post="strain FSS13025, 2 × 104 FFU of ZIKV strain MR766, or"/>
 <result pre="either 1 × 105 FFU of ZIKV strain FSS13025, 2 × 104 FFU of" exact="ZIKV" post="strain MR766, or 1 × 104 FFU of ZIKV strain PRVABC59."/>
 <result pre="2 × 104 FFU of ZIKV strain MR766, or 1 × 104 FFU of" exact="ZIKV" post="strain PRVABC59. Standard flow cytometry-based neutralization assays using U937-DC-SIGN"/>
 <result pre="cells were then performed as described previously58,86,93. Mice and lethal" exact="ZIKV" post="infection model Ifnar1−/− mice (C57BL/6 mice deficient in type"/>
 <result pre="intravenously via the retro-orbital (r.o.) route with 1.0 × 103 FFU of" exact="ZIKV" post="FSS13025. Testing of drug product and treatments ZIKV-IG was"/>
 <result pre="using a microneutralization assay that measured the cytopathic effect of" exact="ZIKV" post="strain PRVABC59 on Vero E6 cells using an xCELLigence®"/>
 <result pre="electric current passing through the electrodes. An equal volume of" exact="ZIKV" post="PRVABC59, diluted to 100 TCID50, was incubated for one"/>
 <result pre="for ZIKV-IG product was 18,480, indicating a high degree of" exact="Zika" post="virus neutralization. Naïve-ZIKV-IG was manufactured using the same processes"/>
 <result pre="or 0.1 mg/kg ZIKV-IG (100 μL/mouse) at 24 hrs following lethal" exact="ZIKV" post="infection. Clinical monitoring of mice and euthanasia criteria Following"/>
 <result pre="Mini Kit (Qiagen) and the RNeasy Mini Kit (Qiagen), respectively." exact="ZIKV" post="RNA levels in sera and tissues were quantified by"/>
 <result pre="Tissue RNA levels were normalized to 18S as described for" exact="Dengue" post="RNA91 and expressed as genome equivalent per 18S (GE/18S),"/>
 <result pre="serum RNA levels were expressed as GE/mL. Quantification of infectious" exact="ZIKV" post="by FFA FFA procedures were performed as previously described52."/>
 <result pre="and serological specificityTrans R Soc Trop Med Hyg19524650952010.1016/0035-9203(52)90042-412995440 3.MarchetteNJGarciaRRudnickAIsolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm J Trop"/>
 <result pre="Cao-Lormeau, V. &amp;amp; Musso, D. Evidence of perinatal transmission of" exact="Zika" post="virus, French Polynesia, December 2013 and February 2014. Euro"/>
 <result pre="February 2014. Euro Surveill19 (2014). 6.CalvetGet al.Detection and sequencing of" exact="Zika" post="virus from amniotic fluid of fetuses with microcephaly in"/>
 <result pre="the Evidence for CausalityN Engl J Med20163741981198710.1056/NEJMsr160433827074377 9.Barjas-CastroMLet al.Probable transfusion-transmitted" exact="Zika" post="virus in BrazilTransfusion2016561684168810.1111/trf.1368127329551 10.MottaIJet al.Evidence for Transmission of Zika"/>
 <result pre="transfusion-transmitted Zika virus in BrazilTransfusion2016561684168810.1111/trf.1368127329551 10.MottaIJet al.Evidence for Transmission of" exact="Zika" post="Virus by Platelet TransfusionN Engl J Med20163751101110310.1056/NEJMc160726227532622 11.MussoDNhanTRobinERocheCBierlaireDZisouKShan YanACao-LormeauVBroultJPotential"/>
 <result pre="Virus by Platelet TransfusionN Engl J Med20163751101110310.1056/NEJMc160726227532622 11.MussoDNhanTRobinERocheCBierlaireDZisouKShan YanACao-LormeauVBroultJPotential for" exact="Zika" post="virus transmission through blood transfusion demonstrated during an outbreak"/>
 <result pre="seroepidemiological investigations in Oyo StateJ Hyg (Lond)19798321321910.1017/S0022172400025997489960 24.FilipeARMartinsCMRochaHLaboratory infection with" exact="Zika" post="virus after vaccination against yellow feverArch Gesamte Virusforsch19734331531910.1007/BF015561474799154 25.OlsonJGKsiazekTGSuhandimanTriwibowoZika"/>
 <result pre="Infect Dis2014201085108610.3201/eid2006.14013824856001 28.PetersenLRJamiesonDJPowersAMHoneinMAZika VirusN Engl J Med20163741552156310.1056/NEJMra160211327028561 29.ZhangQet al.Spread of" exact="Zika" post="virus in the AmericasProc Natl Acad Sci USA2017114E4334E434310.1073/pnas.162016111428442561 30.Colon-GonzalezFJPeresCASteiner"/>
 <result pre="AmericasProc Natl Acad Sci USA2017114E4334E434310.1073/pnas.162016111428442561 30.Colon-GonzalezFJPeresCASteiner Sao BernardoCHunterPRLakeIRAfter the epidemic:" exact="Zika" post="virus projections for Latin America and the CaribbeanPLoS Negl"/>
 <result pre="the CaribbeanPLoS Negl Trop Dis201711e000600710.1371/journal.pntd.000600729091713 31.BrasilPet al.Guillain-Barre syndrome associated with" exact="Zika" post="virus infectionLancet2016387148210.1016/S0140-6736(16)30058-727115821 32.BautistaLESethiAKAssociation between Guillain-Barre syndrome and Zika virus"/>
 <result pre="associated with Zika virus infectionLancet2016387148210.1016/S0140-6736(16)30058-727115821 32.BautistaLESethiAKAssociation between Guillain-Barre syndrome and" exact="Zika" post="virus infectionLancet20163872599260010.1016/S0140-6736(16)30844-327353815 33.de AraujoTVBet al.Association between microcephaly, Zika virus"/>
 <result pre="syndrome and Zika virus infectionLancet20163872599260010.1016/S0140-6736(16)30844-327353815 33.de AraujoTVBet al.Association between microcephaly," exact="Zika" post="virus infection, and other risk factors in Brazil: final"/>
 <result pre="of a case-control studyLancet Infect Dis20181832833610.1016/S1473-3099(17)30727-229242091 34.MartinesRBet al.Pathology of congenital" exact="Zika" post="syndrome in Brazil: a case seriesLancet201638889890410.1016/S0140-6736(16)30883-227372395 35.LuceyDCumminsHSholtsSCongenital Zika Syndrome"/>
 <result pre="of congenital Zika syndrome in Brazil: a case seriesLancet201638889890410.1016/S0140-6736(16)30883-227372395 35.LuceyDCumminsHSholtsSCongenital" exact="Zika" post="Syndrome in 2017JAMA20173171368136910.1001/jama.2017.155328384812 36.MenesesJDAet al.Lessons Learned at the Epicenter"/>
 <result pre="2017JAMA20173171368136910.1001/jama.2017.155328384812 36.MenesesJDAet al.Lessons Learned at the Epicenter of Brazil’s Congenital" exact="Zika" post="Epidemic: Evidence From 87 Confirmed CasesClin Infect Dis2017641302130810.1093/cid/cix16628329257 37.LukeTCKilbaneEMJacksonJLHoffmanSLMeta-analysis:"/>
 <result pre="Q., Yan, J. &amp;amp; Gao, G. F. Monoclonal Antibodies against" exact="Zika" post="Virus: Therapeutics and Their Implications for Vaccine Design. J"/>
 <result pre="50.DingQet al.Species-specific disruption of STING-dependent antiviral cellular defenses by the" exact="Zika" post="virus NS2B3 proteaseProc Natl Acad Sci USA2018115E6310E631810.1073/pnas.180340611529915078 51.GoveroJet al.Zika"/>
 <result pre="and Role of the CD8(+) T Cell Response During Primary" exact="Zika" post="Virus Infection in MiceCell Host Microbe201721354610.1016/j.chom.2016.12.01028081442 53.WenJet al.Dengue virus-reactive"/>
 <result pre="53.WenJet al.Dengue virus-reactive CD8(+) T cells mediate cross-protection against subsequent" exact="Zika" post="virus challengeNat Commun20178145910.1038/s41467-017-01669-z29129917 54.Regla-NavaJAet al.Cross-reactive Dengue virus-specific CD8(+) T"/>
 <result pre="mediate cross-protection against subsequent Zika virus challengeNat Commun20178145910.1038/s41467-017-01669-z29129917 54.Regla-NavaJAet al.Cross-reactive" exact="Dengue" post="virus-specific CD8(+) T cells protect against Zika virus during"/>
 <result pre="Commun20178145910.1038/s41467-017-01669-z29129917 54.Regla-NavaJAet al.Cross-reactive Dengue virus-specific CD8(+) T cells protect against" exact="Zika" post="virus during pregnancyNat Commun20189304210.1038/s41467-018-05458-030072692 55.LazearHMet al.A Mouse Model of"/>
 <result pre="Zika virus during pregnancyNat Commun20189304210.1038/s41467-018-05458-030072692 55.LazearHMet al.A Mouse Model of" exact="Zika" post="Virus PathogenesisCell Host Microbe20161972073010.1016/j.chom.2016.03.01027066744 56.MinerJJet al.Zika Virus Infection during"/>
 <result pre="with Shedding of Virus in TearsCell Rep2016163208321810.1016/j.celrep.2016.08.07927612415 58.WenJet al.Identification of" exact="Zika" post="virus epitopes reveals immunodominant and protective roles for dengue"/>
 <result pre="CD8(+) T cellsNat Microbiol201721703610.1038/nmicrobiol.2017.3628288094 59.DowallSDet al.A Susceptible Mouse Model for" exact="Zika" post="Virus InfectionPLoS Negl Trop Dis201610e000465810.1371/journal.pntd.000465827149521 60.RossiSLet al.Characterization of a"/>
 <result pre="Dis201610e000465810.1371/journal.pntd.000465827149521 60.RossiSLet al.Characterization of a Novel Murine Model to Study" exact="Zika" post="VirusAm J Trop Med Hyg2016941362136910.4269/ajtmh.16-011127022155 61.TangWWet al.A Mouse Model"/>
 <result pre="VirusAm J Trop Med Hyg2016941362136910.4269/ajtmh.16-011127022155 61.TangWWet al.A Mouse Model of" exact="Zika" post="Virus Sexual Transmission and Vaginal Viral ReplicationCell Rep2016173091309810.1016/j.celrep.2016.11.07028009279 62.WangQet"/>
 <result pre="of human neutralizing antibodies isolated from a patient infected with" exact="Zika" post="virusSci Transl Med20168369ra17910.1126/scitranslmed.aai833627974667 63.SapparapuGet al.Neutralizing human antibodies prevent Zika"/>
 <result pre="with Zika virusSci Transl Med20168369ra17910.1126/scitranslmed.aai833627974667 63.SapparapuGet al.Neutralizing human antibodies prevent" exact="Zika" post="virus replication and fetal disease in miceNature201654044344710.1038/nature2056427819683 64.LiCet al.A"/>
 <result pre="64.LiCet al.A Single Injection of Human Neutralizing Antibody Protects against" exact="Zika" post="Virus Infection and Microcephaly in Developing Mouse EmbryosCell Rep2018231424143410.1016/j.celrep.2018.04.00529719255"/>
 <result pre="65.SteinDRet al.Human polyclonal antibodies produced in transchromosomal cattle prevent lethal" exact="Zika" post="virus infection and testicular atrophy in miceAntiviral Res201714616417310.1016/j.antiviral.2017.09.00528893603 66.WangSet"/>
 <result pre="Res201714616417310.1016/j.antiviral.2017.09.00528893603 66.WangSet al.Transfer of convalescent serum to pregnant mice prevents" exact="Zika" post="virus infection and microcephaly in offspringCell Res20172715816010.1038/cr.2016.14427922617 67.DowdKAet al.Broadly"/>
 <result pre="and microcephaly in offspringCell Res20172715816010.1038/cr.2016.14427922617 67.DowdKAet al.Broadly Neutralizing Activity of" exact="Zika" post="Virus-Immune Sera Identifies a Single Viral SerotypeCell Rep2016161485149110.1016/j.celrep.2016.07.04927481466 68.KammanadimintiSet"/>
 <result pre="model of inhalational anthraxPLoS One20149e10639310.1371/journal.pone.010639325226075 69.AliotaMTet al.Heterologous Protection against Asian" exact="Zika" post="Virus Challenge in Rhesus MacaquesPLoS Negl Trop Dis201610e000516810.1371/journal.pntd.000516827911897 70.GuzmanMGet"/>
 <result pre="antibody responses after dengue virus infection are highly cross-reactive to" exact="Zika" post="virusProc Natl Acad Sci USA20161137852785710.1073/pnas.160793111327354515 82.StettlerKet al.Specificity, cross-reactivity, and"/>
 <result pre="USA20161137852785710.1073/pnas.160793111327354515 82.StettlerKet al.Specificity, cross-reactivity, and function of antibodies elicited by" exact="Zika" post="virus infectionScience201635382382610.1126/science.aaf850527417494 83.BardinaSVet al.Enhancement of Zika virus pathogenesis by"/>
 <result pre="of antibodies elicited by Zika virus infectionScience201635382382610.1126/science.aaf850527417494 83.BardinaSVet al.Enhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunityScience201735617518010.1126/science.aal436528360135 84.GeorgeJet al.Prior Exposure"/>
 <result pre="virus pathogenesis by preexisting antiflavivirus immunityScience201735617518010.1126/science.aal436528360135 84.GeorgeJet al.Prior Exposure to" exact="Zika" post="Virus Significantly Enhances Peak Dengue-2 Viremia in Rhesus MacaquesSci"/>
 <result pre="Enhances Peak Dengue-2 Viremia in Rhesus MacaquesSci Rep201771049810.1038/s41598-017-10901-128874759 85.WatanabeSTanNWWChanKWKVasudevanSGDengue and" exact="Zika" post="Virus Serological Cross-reactivity and their Impact on Pathogenesis in"/>
 <result pre="Impact on Pathogenesis in MiceJ Infect Dis201810.1093/infdis/jiy482 86.FowlerAMet al.Maternally Acquired" exact="Zika" post="Antibodies Enhance Dengue Disease Severity in MiceCell Host Microbe201824743750"/>
 <result pre="in MiceJ Infect Dis201810.1093/infdis/jiy482 86.FowlerAMet al.Maternally Acquired Zika Antibodies Enhance" exact="Dengue" post="Disease Severity in MiceCell Host Microbe201824743750 e74510.1016/j.chom.2018.09.01530439343 87.AbbinkPet al.Protective"/>
 <result pre="Microbe201824743750 e74510.1016/j.chom.2018.09.01530439343 87.AbbinkPet al.Protective efficacy of multiple vaccine platforms against" exact="Zika" post="virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 88.LaroccaRAet al.Vaccine protection against"/>
 <result pre="Zika virus challenge in rhesus monkeysScience20163531129113210.1126/science.aah615727492477 88.LaroccaRAet al.Vaccine protection against" exact="Zika" post="virus from BrazilNature201653647447810.1038/nature1895227355570 89.HeangVet al.Zika virus infection, Cambodia, 2010Emerg"/>
 <result pre="al.Zika virus infection, Cambodia, 2010Emerg Infect Dis20121834935110.3201/eid1802.11122422305269 90.LanciottiRSLambertAJHolodniyMSaavedraSSignor LdelCPhylogeny of" exact="Zika" post="Virus in Western Hemisphere, 2015Emerg Infect Dis20162293393510.3201/eid2205.16006527088323 91.PrestwoodTRPrigozhinDMShararKLZellwegerRMShrestaSA mouse-passaged"/>
 <result pre="al.CD4+ T cells promote humoral immunity and viral control during" exact="Zika" post="virus infectionPLoS Pathog201915e100747410.1371/journal.ppat.100747430677097"/>
</results>
